Safety of abiraterone acetate (AA) in castration-resistant prostate cancer (CRPC) patients with concomitant cardiovascular disease.

被引：0
|
作者：
Procopio, Giuseppe
Verzoni, Elena
Testa, Isabella
Biasoni, Davide
Torelli, Tullio
Nicolai, Nicola
Salvioni, Roberto
Valdagni, Riccardo
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SAFETY OF ABIRATERONE ACETATE (AA) IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND CONCOMITANT CARDIAC RISK
    Procopio, G.
    Verzoni, E.
    Testa, I.
    Stagni, S.
    Villa, S.
    Valdagni, R.
    De Braud, F. G. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 305 - 305
  • [2] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [3] Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC)
    Bianchini, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).
    Harshman, Lauren Christine
    Werner, Lillian
    Nakabayashi, Mari
    Tripathi, Abhishek
    Mckay, Rana R.
    Wang, Xiaodong
    Pomerantz, Mark
    Mucci, Lorelei A.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    Lee, Gwo-Shu Mary
    Kantoff, Philip W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [5] Clinical benefit on abiraterone acetate (AA) in patients (pts) with PTEN loss castration-resistant prostate cancer (CRPC)
    Omlin, A.
    Pezaro, C.
    Reid, A.
    Rodrigues, D. Nava
    Riisnaes, R.
    Miranda, S.
    Tunariu, N.
    Lorente, D.
    Attard, G.
    De Bono, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S707 - S707
  • [6] Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation
    Prati, Veronica
    Ruatta, Fiorella
    Aversa, Caterina
    Gernone, Angela
    Galizia, Danilo
    Bonzano, Alessandro
    Torino, Sofia
    Nuzzolese, Imperia
    Marandino, Laura
    Aglietta, Massimo
    Ortega, Cinzia
    [J]. FUTURE ONCOLOGY, 2018, 14 (05) : 443 - 448
  • [7] Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
    Verzoni, Elena
    Grassi, Paolo
    Ratta, Raffaele
    Niger, Monica
    De Braud, Filippo
    Valdagni, Riccardo
    Procopio, Giuseppe
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (05) : 323 - 330
  • [8] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    [J]. ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [10] ABIRATERONE ACETATE: PROSPECTIVE EVALUATION OF THE CARDIOVASCULAR SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
    Ruatta, Fiorella
    Prati, Veronica
    Aversa, Caterina
    Gernone, Angela
    Galizia, Danilo
    Bonzano, Alessandro
    Torino, Sofia
    Nuzzolese, Imperia
    Marandino, Laura
    Aglietta, Massimo
    Ortega, Cinzia
    [J]. ANTICANCER RESEARCH, 2016, 36 (05) : 2615 - 2615
12345